 | | Vol. 13.24 – 21 June, 2022 |
| |
|
|
| Investigators used in situ barcoding and classical fate mapping to assess the developmental and clonal origins of adult blood in mice.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists report that bone marrow hematopoietic stem and progenitor cells are skewed toward myeloid lineage concomitant with the clonal expansion of T cells in multiple sclerosis patients.
[Cell] |
|
|
|
| Using single-cell RNA sequencing, researchers showed a continuous landscape of highly purified human bone marrow hematopoietic stem cells displaying varying degrees of dormancy.
[Nature Cell Biology] |
|
|
|
| Scientists identified a novel, previously unannotated oncogenic RNA-splicing derived isoform of EVI1 which is frequently present in inv(3)/t(3;3) AML and directly contributes to leukemic transformation.
[Blood] |
|
|
|
| Researchers investigated if DNA methyltransferase 3A is essential for hematopoietic differentiation of human induced pluripotent stem cells (iPSCs).
[BMC Biology] |
|
|
|
| The authors demonstrated that CD49b subdivides the most primitive hematopoietic stem cell (HSC) compartment into functionally distinct subtypes: CD49b− HSCs are highly enriched for myeloid-biased and the most durable cells, while CD49b+ HSCs are enriched for multipotent cells with lymphoid bias and reduced self-renewal ability.
[Stem Cell Reports] |
|
|
|
| Two hESCs and one hiPSC lines were differentiated into a hematoendothelial population, hPSC-ECs and blast colonies via CD144+-embryoid bodies.
[Stem Cell Research & Therapy] |
|
|
|
| Researchers identified Pumilo-1 (PUM1), an RNA binding protein with no previously reported functions in erythropoiesis, as a direct post-transcriptional regulator of β-globin switching.
[Blood Advances] |
|
|
|
| | Scientists identified patients with acute myeloid leukemia who underwent hematopoietic stem cell transplantation and had existing baseline plasma samples. Using those samples, they studied 65 blood based metabolomic and 61 immune/inflammatory related biomarkers, comparing patients with either long-term overall survival (OS) or short-term OS.
[PLoS One] |
|
|
|
|
| The authors explore the relationship between mutations in genes causing clonal hematopoiesis of indeterminate potential (CHIP) and atherothrombotic disorders, along with potential mechanisms of enhanced clonal outgrowth and potential therapies and strategies to slow CHIP progression.
[Thrombosis and Haemostasis] |
|
|
|
|
| Bristol Myers Squibb announced that the European Medicines Agency has validated its type II variation application for extension of the indication for Breyanzi to treat adult patients with diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B, who are refractory or have relapsed within 12 months of initial therapy and are candidates for hematopoietic stem cell transplant.
[Bristol Myers Squibb] |
|
|
|
|
| July 10 – July 13
Toronto, Ontario, Canada |
|
|
|
|
|
| | American Association for Cancer Research – Various, United States |
|
|
|
| | Francis Crick Institute – London, England, United Kingdom |
|
|
|
| | Albert Einstein College of Medicine – New York, New York, United States |
|
|
|
| | Van Andel Institute – Grand Rapids, Michigan, United States |
|
|
|
| | Columbia University – New York, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
